Cannovex

Agoralaan Building Abis /

3590 Diepenbeek

BE

Cannovex

Foundation date

06/08/2016

Sector

#Biotechnology - other

Subsector

Therapeutic areas

Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.

Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.

Upcoming events

Latest news

  • Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

    Wednesday March 27th 2024

  • InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline

    Tuesday March 26th 2024

  • Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

    Monday March 25th 2024